Pharmacy Times Ð October 2008
Drug Interactions: Insights and Observations
Protease Inhibitors and PPIs
John R. Horn, PharmD,
FCCP and Philip D. Hansten, PharmD
References
- Luber A et al. Survey of
medication used by HIV-infected patients that affected gastrointestinal
(GI) acidity and potential for negative drug interactions with HAART
[abstract no. P294], 7th International Congress on Drug Therapy
in HIV infection; 2004; Glasgow.
- .Agarwala S et al.
Pharmacokinetic interaction between atazanavir and omeprazole in healthy
subjects [abstract no. WePe3.3C08], 3rd International AIDS
Society Conference on HIV Pathogenesis and Treatment; 2005; Rio de
Janeiro.
- Agarwala S et al. pharmacokinetic
effect of omeprazole on atazanavir co-administered with ritonavir in
healthy subjects [abstract no. 658] 12th Conference on
Retroviruses and Opportunistic Infections; 2005; Boston.
- Tomilo DL et al. Inhibition of
atazanavir oral absorption by lansoprazole gastric acid suppression in
healthy volunteers. Pharmacotherapy. 2006;26:341-6.
- Guiard-Schmid JB
et al. Proton pump inhibitors do not reduce atazanavir
concentrations in HIV-infected patients treated with ritonavir-boosted
atazanavir [letter]. AIDS 2005;19:1937-8.
- Burger DM et al.
pharmacokinetic interaction between the proton pump inhibitor omeprazole
and the HIV protease inhibitor indinavir. AIDS. 1998;12:2080-2.
- Tappouni HL et al. Effect of
omeprazole on the plasma concentrations of indinavir when administered
alone and in combination with ritonavir. Am J Health Syst Pharm. 2008;65:422-8.
- Fang AF et al. Significant
decrease in nelfinavir systemic exposure after omeprazole coadministration
in healthy subjects. Pharmacotherapy. 2008;28:42-50.
- Winston A et al. Effect of
omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with
ritonavir in healthy male and female volunteers. AIDS. 2006;20:1401-6.
- Singh K et al.
Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in
HIV-infected subjects. Clin Pharmacol Ther. 2008;83:867-72.